We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) closed at $667.24 in the latest trading session, marking a +0.27% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.26%. Elsewhere, the Dow lost 0.16%, while the tech-heavy Nasdaq lost 0.04%.
Prior to today's trading, shares of the maker of scientific instrument and laboratory supplies had gained 6.03% over the past month. This has outpaced the Medical sector's gain of 5.77% and the S&P 500's gain of 4.82% in that time.
Wall Street will be looking for positivity from Thermo Fisher Scientific as it approaches its next earnings report date. In that report, analysts expect Thermo Fisher Scientific to post earnings of $4.82 per share. This would mark a year-over-year decline of 32.02%. Our most recent consensus estimate is calling for quarterly revenue of $8.62 billion, down 18.33% from the year-ago period.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $23.40 per share and revenue of $37.13 billion. These results would represent year-over-year changes of +19.69% and +15.25%, respectively.
It is also important to note the recent changes to analyst estimates for Thermo Fisher Scientific. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Thermo Fisher Scientific currently has a Zacks Rank of #2 (Buy).
Looking at its valuation, Thermo Fisher Scientific is holding a Forward P/E ratio of 28.44. Its industry sports an average Forward P/E of 42.51, so we one might conclude that Thermo Fisher Scientific is trading at a discount comparatively.
Meanwhile, TMO's PEG ratio is currently 2.03. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.6 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
Thermo Fisher Scientific (TMO - Free Report) closed at $667.24 in the latest trading session, marking a +0.27% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.26%. Elsewhere, the Dow lost 0.16%, while the tech-heavy Nasdaq lost 0.04%.
Prior to today's trading, shares of the maker of scientific instrument and laboratory supplies had gained 6.03% over the past month. This has outpaced the Medical sector's gain of 5.77% and the S&P 500's gain of 4.82% in that time.
Wall Street will be looking for positivity from Thermo Fisher Scientific as it approaches its next earnings report date. In that report, analysts expect Thermo Fisher Scientific to post earnings of $4.82 per share. This would mark a year-over-year decline of 32.02%. Our most recent consensus estimate is calling for quarterly revenue of $8.62 billion, down 18.33% from the year-ago period.
TMO's full-year Zacks Consensus Estimates are calling for earnings of $23.40 per share and revenue of $37.13 billion. These results would represent year-over-year changes of +19.69% and +15.25%, respectively.
It is also important to note the recent changes to analyst estimates for Thermo Fisher Scientific. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Thermo Fisher Scientific currently has a Zacks Rank of #2 (Buy).
Looking at its valuation, Thermo Fisher Scientific is holding a Forward P/E ratio of 28.44. Its industry sports an average Forward P/E of 42.51, so we one might conclude that Thermo Fisher Scientific is trading at a discount comparatively.
Meanwhile, TMO's PEG ratio is currently 2.03. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Instruments stocks are, on average, holding a PEG ratio of 2.6 based on yesterday's closing prices.
The Medical - Instruments industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 176, which puts it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.